PROCEPT BioRobotics (NASDAQ:PRCT) Announces Earnings Results, Misses Estimates By $0.07 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) posted its earnings results on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.07), FiscalAI reports. The firm had revenue of $98.29 million during the quarter, compared to analyst estimates of $100.52 million. PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.

Here are the key takeaways from PROCEPT BioRobotics’ conference call:

• PROCEPT reported third-quarter revenue of $98.3 million, up 18% year over year, with U.S. procedures rising 22% and U.S. handpiece and consumable revenue increasing 21%. Handpiece pricing remained strong, and the company said field inventory had normalized.
• Procedure growth remains challenged by weaker utilization on legacy AquaBeam systems as surgeons shift cases to HYDROS; HYDROS accounts performed more than 35% more procedures than legacy accounts. Management expects about 54,000 procedures for 2026, within its guidance range, but reaching that level implies the strongest sequential procedure growth of the year in Q4.
• The company placed 62 HYDROS systems, including 20 replacements, at an average U.S. selling price of about $495,000. Although greenfield placements fell short of expectations in Q3 due largely to timing, management maintained that it expects to meet or exceed its initial full-year system targets and said capital demand remains healthy.
• The net loss widened to $26.5 million from $21.4 million a year earlier, and adjusted EBITDA loss increased to $9.8 million from $7.4 million as operating expenses rose with investment. Management expects positive adjusted EBITDA in Q4 and described approximately 20% revenue growth in 2027 as a planning baseline, while noting that formal guidance will come later.

PROCEPT BioRobotics Trading Up 7.4%

Shares of PRCT stock traded up $1.49 during mid-day trading on Wednesday, hitting $21.66. The company’s stock had a trading volume of 2,828,443 shares, compared to its average volume of 1,502,198. The company has a market cap of $1.24 billion, a PE ratio of -11.16 and a beta of 0.88. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55. The company’s fifty day simple moving average is $19.33 and its 200-day simple moving average is $23.27. PROCEPT BioRobotics has a 52 week low of $16.67 and a 52 week high of $38.11.

Insider Activity at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Larry Wood bought 23,900 shares of the stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the acquisition, the chief executive officer owned 23,900 shares in the company, valued at $498,315. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. In the last 90 days, insiders sold 1,043 shares of company stock worth $21,851. 4.00% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Jefferies Financial Group reissued a “hold” rating and set a $20.00 target price on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. Wells Fargo & Company downgraded PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price target for the company. in a research note on Wednesday, August 5th. UBS Group downgraded PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 target price on the stock. in a report on Tuesday, July 28th. Truist Financial set a $21.00 price objective on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Finally, William Blair downgraded PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Three analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $25.50.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. The company’s technology is designed to provide a minimally invasive alternative to conventional surgical procedures.

Its primary product is the AquaBeam Robotic System, which uses image guidance, robotic assistance and a high-velocity waterjet to remove targeted prostate tissue.